SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-09T09:09:23.106819+00:00","dedupe_key":"signal_enriched:discovery_ipo_delta:c60ed5838cb4e74f","evidence_event_ids":["evt_0b6d64e676d2"],"signal_type":"discovery_ipo_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPcFZWdHJPM0EwWVppZ2ltYi1Vc05GeE5jYTdFanlNUkFXc0JUeEhCcUlEazV6UFFFM3hTRE00ZVAwQVN5NmpHV1BZSWpfei1leU5nTTZOaGhnOTEwTDgxOE1JcXVqaXl5d3d5enpud3loWURCY1NqSS04NkxhcFhTb244THlKMHljeFcxN1Rkc3FQVmtTbjFHYmFXc3hTaU9kNTgxVmVrdHlxa3h0bEREc1Nxd25KSEUxaWc?oc=5","as_of":"2026-04-09T09:09:23.106819+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPcFZWdHJPM0EwWVppZ2ltYi1Vc05GeE5jYTdFanlNUkFXc0JUeEhCcUlEazV6UFFFM3hTRE00ZVAwQVN5NmpHV1BZSWpfei1leU5nTTZOaGhnOTEwTDgxOE1JcXVqaXl5d3d5enpud3loWURCY1NqSS04NkxhcFhTb244THlKMHljeFcxN1Rkc3FQVmtTbjFHYmFXc3hTaU9kNTgxVmVrdHlxa3h0bEREc1Nxd25KSEUxaWc?oc=5","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_4875a53f390c0237","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T02:12:55.063648+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPcFZWdHJPM0EwWVppZ2ltYi1Vc05GeE5jYTdFanlNUkFXc0JUeEhCcUlEazV6UFFFM3hTRE00ZVAwQVN5NmpHV1BZSWpfei1leU5nTTZOaGhnOTEwTDgxOE1JcXVqaXl5d3d5enpud3loWURCY1NqSS04NkxhcFhTb244THlKMHljeFcxN1Rkc3FQVmtTbjFHYmFXc3hTaU9kNTgxVmVrdHlxa3h0bEREc1Nxd25KSEUxaWc?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"gstatic.com","publisher_resolution":"canonical_aggregator_unresolved","requested_url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPcFZWdHJPM0EwWVppZ2ltYi1Vc05GeE5jYTdFanlNUkFXc0JUeEhCcUlEazV6UFFFM3hTRE00ZVAwQVN5NmpHV1BZSWpfei1leU5nTTZOaGhnOTEwTDgxOE1JcXVqaXl5d3d5enpud3loWURCY1NqSS04NkxhcFhTb244THlKMHljeFcxN1Rkc3FQVmtTbjFHYmFXc3hTaU9kNTgxVmVrdHlxa3h0bEREc1Nxd25KSEUxaWc?oc=5","source_event_id":"evt_0b6d64e676d2","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"c865b71ab513f764","kind":"ipo_calendar","published_at":"2026-04-09T08:13:27+00:00","publisher_domain":"gstatic.com","signal_understanding":{"analysis_basis":"headline_and_summary","claim_confidence":0.78,"dates_mentioned":[],"entities":[{"asset_class":"equity","name":"Avalyn","relevance":"high","symbol":"","type":"company"},{"asset_class":"media","name":"Fierce Biotech","relevance":"medium","symbol":"","type":"publisher"}],"event_type":"listing","information_gaps":["No IPO timing (date/quarter) is provided in the provided text.","No amount to be raised, offering size, or underwriters are provided.","No specific approved respiratory drugs or inhaled product candidates are named.","No trial design details (endpoints, locations, enrollment) are provided.","The provided article text appears to contain only page styling/HTML and not the substantive article content; extraction is therefore based on the headline/source summary only."],"key_facts":["The signal states that Avalyn plans an IPO.","The stated purpose of the IPO is to fund phase 3 trials.","The phase 3 trials are for inhaled versions of approved respiratory drugs."],"numeric_claims":[],"primary_claim":"Avalyn plans an IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Avalyn is planning an IPO to raise funding for phase 3 trials of inhaled versions of approved respiratory drugs.","topics":["IPO","phase 3 trials","inhaled drug formulations","respiratory drugs","funding strategy"]},"source":"Fierce Biotech","source_domain":"gstatic.com","summary":"Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs Fierce Biotech","tickers":[],"title":"Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs - Fierce Biotech","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 12740 in events